Hypertension (HTN) is considered one of the leading causes of increased cardiovascular disease.
The 2017 American College of Cardiology (ACC) and American Heart Association (AHA) definition of HTN stages is:
In the 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: all patients with elevated blood pressure are recommended to have lifestyle modifications as initial treatment, including weight loss, healthy heart diet, increased physical activity, low sodium diet, and limitation of alcohol consumption.
In patients with stage 1 HTN recommendations are to start antihypertensive medications if the patient has a 10-year ASCVD risk of 10% or higher with a target of BP less than 130/80 to prevent patients from cardiovascular events. The recommendation is for patients with stage 1 HTN and 10-year ASCVD risk less than 10% to have lifestyle modification measures.
Recommendations are for all patients with stage 2 HTN to start antihypertensive medications to lower BP to a target lower than 130/80 even if the 10-year ASCVD risk is less than 10%.
In patients with chronic kidney disease, the target BP is 130/80
Patients with type 2 diabetes mellitus (T2DM) it is recommended to start on antihypertensive medications if BP is more than 130/80 with a goal of BP lower than 130/80.
Antihypertensive medication treatment usually starts as monotherapy after failure of conservative management with lifestyle modification. The use of combination therapy is common when patients fail the monotherapy approach.
Lowering blood pressure does reduce cardiovascular risks, maintaining systolic blood pressure less than 130 mm Hg has shown to prevent complications in patients with heart failure, diabetes, coronary artery disease, stroke, and other cardiovascular diseases. The response to initial monotherapy is affected by age and race.
There are multiple classes of antihypertensive medications used for the treatment of HTN; the most recommended classes used as first-line for treatment are:
Calcium channel blockers
Angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs)
Thiazide and thiazide-like diuretics are usually the first-line of treatment for hypertension; in JNC8 guidelines the thiazide diuretics can be used as the first-line treatment for HTN (either alone or in combination with other antihypertensives) in all age groups regardless of race unless patient has evidence of chronic kidney disease where angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker is indicated.
The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial ALLHAT study recommended thiazide diuretics as the first line of treatment for hypertension unless there are contraindications.
Treatment with hydrochlorothiazide as a single agent with a dose of 12.5 mg or 25 mg daily showed no evidence of decreasing morbidity or mortality.
Thiazide-type diuretics (chlorthalidone and indapamide) have demonstrated to be superior to prevent cardiovascular disease at a lower cost. Recommendations are to start them as first-line treatment for hypertension. Multiple studies have shown that thiazide-like diuretics (chlorthalidone and indapamide) are more potent than hydrochlorothiazide in hypertension treatment. They are better at decreasing the risk of cardiovascular disease comparing to hydrochlorothiazide.
Chlorthalidone is the drug of choice to start as monotherapy for hypertension. Studies show it to be the best diuretic to control blood pressure and to prevent mortality and morbidity. It is more effective than hydrochlorothiazide in lowering blood pressure when the researchers monitored 24-hour ambulatory blood pressures. Hydrochlorothiazide has a shorter effect during the day in a study that compared the office blood pressure reading with the 24 hours ambulatory blood pressure readings. Switching to chlorthalidone from hydrochlorothiazide decreases systolic blood pressure by 7 to 8 mm Hg.
The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) showed that chlorthalidone at 12.5 to 25 mg/day caused less cardiovascular complications than amlodipine and lisinopril
Chlorthalidone is the first choice for older patients with osteoporosis, as it showed less incidence of pelvic fractures when compared to amlodipine and lisinopril. Chlorthalidone, when compared with doxazosin mesylate, was better in preventing cardiovascular disease, when compared with lisinopril was found to be better in preventing cardiovascular disease including strokes and heart failure incidence, and when compared with amlodipine was better in preventing heart failure.
Calcium channel blockers CCBs
Same as thiazide-type diuretics CCBs are recommended in JNC8 guidelines to be used as a first-line treatment alone or in combination with other antihypertensives in all patients with HTN regardless of age and race with the exception of patients with chronic kidney disease where ACE inhibitors or ARBs are the recommended first-line treatment.
CCBs are shown to decrease all cardiovascular events other than heart failure similar to thiazide diuretics, and they can be used as the best alternative to thiazides when patients do not tolerate thiazides.
CCBs divide into two groups: dihydropyridines and non-dihydropyridines
Dihydropyridines are more potent as vasodilators and used more for HTN treatment. They have less effect on heart contractility and conduction. For this, they are used more for the management of HTN. Nifedipine and amlodipine are the most used medications in this group.
Non-dihydropyridines are less potent as vasodilators and have a better effect on cardiac contractility and conduction. They are used more as antiarrhythmic medications and less for HTN treatment.
For African descent patients, initial treatment for hypertension (without evidence of heart failure or chronic kidney disease) should include CCB or a thiazide diuretic.
Long-acting nifedipine has greater antihypertensive action when compared to amlodipine.
Dihydropyridines should not be a primary treatment for congestive heart failure (CHF) but are a safe additional treatment in these patients for better blood pressure control or angina pectoris.
Non-dihydropyridines are relatively contraindicated in patients with CHF with reduced ejection fraction, second and third-degree heart blocks, and in patients with sick sinus syndrome.
When compared to valsartan in a study, amlodipine was found to have better control of 24-hour ambulatory blood pressure. In the ASCOT trial, amlodipine was found to be better than atenolol in lowering the risk of cardiovascular disease and is associated with less risk of diabetes development. When compared to thiazide diuretics, amlodipine was equally effective in lowering cardiovascular disease risk regardless of patient's weight, while thiazides are less effective in normal body mass index (BMI) patients than in patients with obesity.
ACE inhibitors and ARBs
ACE inhibitors and ARBs are the antihypertensive of choice for patients with heart failure and chronic kidney disease. They are indicated as first-line treatment for patients with chronic kidney disease with evidence of proteinuria. JNC8 guidelines list these two classes of antihypertensive medications as first-line treatment for HTN for non-black patients, along with thiazides and CCBs.
Independent of their antihypertensive effect, they are proven to have cardio-protective effect in patients who carry a high risk of cardiovascular disease
Both classes have similar efficacy and share the same indications for treatment, they are both recommended as first-line treatment for patients with left ventricular dysfunction, and ST-elevation MI or non-ST elevation MI with the presence of diabetes, systolic dysfunction or anterior infarct.
Thiazide is better than ACE inhibitors in decreasing blood pressure and preventing stroke, CCBs are better than ACE inhibitors in lowering blood pressure, and in preventing from stroke and heart failure.
Ramipril has shown to decrease mortality, the incidence of stroke, and MIs when used in patients with symptomatic heart failure or asymptomatic patients with low ejection fraction. The research found perindopril to decrease cardiovascular events when used in a patient with stable coronary artery disease and normal systolic dysfunction. When compared with Atenolol, Losartan was found to be better in decreasing morbidity and mortality and better in lowering blood pressure.
Comparing ramipril with telmisartan, they were equivalent in effect in diabetic or heart failure patients, with telmisartan correlating with less angioedema.
Beta-blockers are not indicated as primary treatment for hypertension unless there is a specific indication of heart failure and myocardial infarction.
Beta-blockers are associated with decreased cardiovascular morbidity and mortality when used in younger patients, but less protective in patients older than 65 and were noted to be associated with increased risk of strokes.
When a patient fails a monotherapy for HTN, a combination should merit consideration. A combination of two antihypertensive medications should be a therapeutic option for patients with stage 2 hypertension. One study showed a reduction in blood pressure when drugs from two different classes are combined is about five times greater than when the dose of one drug dose doubles.
A combination of ARB-diuretic or ACE inhibitor-CBB is superior to the beta-blocker-diuretic combination. The beta-blocker and diuretic combination is associated with a higher incidence of diabetes. Clinicians should use combinations that contain beta-blockers when beta-blockers are indicated as in patients with heart failure, tachycardia, or post-MI patients. Combination of thiazide with a potassium-sparing diuretic is as effective as CCB monotherapy in HTN management and showed less incidence of hypokalemia when compared to hydrochlorothiazide monotherapy 
Combination of CCB and diuretics are less available as ARBs or ACE inhibitors based combinations are preferred when a combination is required, these types of combinations (ACE inhibitors or ARBs based combinations) should be used in patients with CKD.
The combination of benazepril-amlodipine is superior to benazepril-hydrochlorothiazide combination in decreasing the incidence of cardiovascular events in patients with high risk, and it decreases the progression of nephropathy.
When the combination of 2 medications does not achieve the treatment goal, a third agent should be added, which is usually done by adding a third agent of the first line group of medications (thiazide-like diuretics, CCB, ACE inhibitors, and ARBs).
When the patient fails the three-drug regimen, the clinician should consider treatment for resistant HTN, adding a fourth antihypertensive agent can be from any of the other classes.
Loop diuretics are more effective than thiazides in patients with a low estimated glomerular filtration rate of less than 30 mL/min. They have approval for the treatment of peripheral edema associated with congestive heart failure and other noncardiac causes of edema as in liver and kidney diseases. Loop diuretics are not first-line agents for HTN treatment.
Potassium Sparing Diuretics: "Mineralocorticoid receptor antagonists" are not usually used as first-line treatment. Spironolactone and eplerenone are considered good in hypertension treatment when added to other antihypertensive medications in resistant HTN, this group of medication is effective when added to triple hypertension medications regimen but should be used cautiously when added to ACE inhibitors or ARBs due to higher incidence of hyperkalemia. They are effective in the treatment of heart failure as they are proven to decrease mortality rates, and they help to decrease hypokalemia rates. Spironolactone is superior to doxazosin and bisoprolol in lowering blood pressure when added to first-line antihypertensive agents in treating resistant hypertension.
Hydralazine can be added for treatment of resistant hypertension, either alone or in combination with nitrates, in case of heart failure. Hydralazine is associated with increased sympathetic tone and increases sodium avidity, adding beta-blocker, and loop diuretics help to decrease these effects.
Clonidine: is a central alpha-2 agonist, it is not a first-line therapy, but can be used as an additional agent when the patient fails combination therapy, the transdermal form is preferred.
Minoxidil is usually an option when the patient fails treatment with hydralazine, it usually provides good blood pressure control, but it is associated with fluid retention, for which adding a loop diuretic is helpful. It increases the sympathetic tone that may require adding a beta-blocker.
Alpha-blockers should not be used in the treatment of hypertension as a first-line agent because they are not as effective in the prevention of cardiovascular disease when compared with other first-line agents.
Thiazide and Thiazide like diuretics: mechanism of action for thiazide-type diuretics is not fully understood. Thiazides inhibit the transport of sodium in the distal tubule; this occurs by blocking the Na/Cl channels. Thiazides can have a small effect on the proximal tube by impairing sodium transport, but the main action is on the distal tubule. Thiazides cause initial volume depletion associated with decreased cardiac output which recovers within 6 to 8 weeks of starting the treatment in a reverse autoregulation mechanism while the blood pressure remains controlled, thiazide diuretics can acutely activate the renin-angiotensin system and cause systemic vascular resistance which prevents a good response to the diuretic treatment, this increase in renin-angiotensin activity may resolve with chronic thiazide treatment, addition of ACE inhibitor or ARB can enhance the blood pressure control. Also, the thiazide-type diuretics have a modest vasodilation effect, although the mechanism is still unclear.
Calcium channel blockers: The mechanism of action of CCBs is related to inhibition of Ca2+ entry to the cells; this occurs by binding to the L-type voltage-gated calcium channels located in the heart muscle. This effect can cause peripheral vasodilation, which is seen mainly in dihydropyridines, or negative inotropic effect on the heart muscle in non-dihydropyridines, which inhibits the sinoatrial and atrioventricular nodes leading to slow cardiac contractility and conduction.
ACE inhibitors decrease the blood pressure by inhibiting the angiotensin-converting enzyme, this causes a decline in the production of angiotensin II, and increases the bradykinin level, by inhibiting its degeneration, which leads to vasodilation.
ARBs work by blocking the binding of angiotensin II to the angiotensin 1 AT1 receptors, which inhibit the angiotensin II effect. In contrast to ACE inhibitors, ARBs do not affect the kinin levels.
Beta-blockers work by inhibiting the catecholamines from binding to the Beta 1,2 and 3 receptors. Beta-1 receptors are found primarily in the heart muscle, beta-2 receptors are located in the bronchial and peripheral vascular smooth muscles, and beta-3 receptors appear in adipose tissue of the heart. Cardio-selective beta-blockers (e.g., metoprolol succinate, metoprolol tartrate, atenolol, betaxolol, and acebutolol) inhibit only beta-1 receptors and cause fewer bronchospasms. By inhibiting the catecholamines binding to the beta receptors, the beta-blockers have a negative inotropic effect, which results in vasodilation of coronary and peripheral arteries and decreases the heart rate, which helps to reduce the oxygen consumption.
Loop diuretics work by increasing the sodium exertion at the level of the medullary and cortical aspects of the thick ascending limb. This action causes a decrease in volume, which leads to decreased blood pressure.
Potassium Sparing Diuretics: Act on the principle cells which are in the late distal tubule and the collecting duct, they inhibit the sodium reabsorption at this level in association with decreased exertion of potassium and hydrogen ions. Spironolactone and eplerenone are considered mineralocorticoid receptor antagonists, and they inhibit the mineralocorticoid receptor.
Hydralazine is an arteriolar vasodilator; it inhibits Ca2+ release in the smooth muscles of the vessels by decreasing its cytoplasmic concentration.
Clonidine: stimulates alpha-2 receptors located in the rostral ventrolateral medulla, which reduces the sympathetic outflow from the central nervous system and decreases plasma norepinephrine levels leading to decreased cardiac output.
Minoxidil is an arteriolar vasodilator; it opens the adenosine triphosphate-sensitive potassium channels located in the smooth muscles of the vessels.
Alpha-blockers act by inhibiting alpha-1 receptors, which decrease vascular smooth muscle contractions, leading to vasodilation.
Thiazide type diuretics are given only as oral forms, Hydrochlorothiazide is available in 12.5 and 25 mg tablets, but the daily dose can be up to 50 mg daily. Chlorthalidone is available in 25 and 50 mg tablets, but the daily dose can be up to 100 mg daily.
Dihydropyridine calcium channel blockers are administered orally. Amlodipine's maximum dose is 10 mg daily. Nifedipine extended-release maximum dose is 120 mg daily. Non-dihydropyridine CCBs are available in oral and intravenous forms; diltiazem intravenous IV form is useful for heart rate control in cardiac arrhythmias. The maximum oral dose of diltiazem is 480 mg daily. Verapamil is available in oral and IV forms as well. The IV form is used for tachyarrhythmias, especially atrial fibrillation. Oral verapamil dose can by up to a maximum of 480 mg daily.
Clonidine transdermal form is the preferred method of administration as the oral forms can increase the risk of rebound hypertension. Transdermal maximum clonidine dose is 0.3 mg weekly, while oral immediate-release form maximum dose is 0.3 mg three times daily.
Minoxidil is given orally for hypertension treatment. Alpha-blockers are available only orally for hypertension treatment.
Thiazides Side effects
Thiazide and thiazide-like diuretics are associated with multiple side effects. Most of these side effects are directly related to the dose of the diuretic, hypokalemia, and hyponatremia are the most common metabolic effects, followed by hyperuricemia, hypomagnesemia, hyperlipidemia, and increased glucose levels.
Chlorthalidone was found in a study to have an increased risk of hospitalization due to severe hypokalemia in the elderly. Other non-dose related side effects are sexual dysfunction and sleep disturbance.
CCB Side effects
The treatment with dihydropyridine CCBs is often associated with peripheral edema. Long-acting nifedipine is associated with a higher incidence of edema when compared to amlodipine; the edema is related to the dose of the CCB. It is not related to sodium or fluid retention nor to developing heart failure. Since CCBs induced edema is not a result of volume increase, it does not improve with diuretics therapy, on the other hand, the combination of CCBs with ACE inhibitors, or with ARBs to a lesser effect, showed decreased risk of developing peripheral edema. Dihydropyridines can cause lightheadedness, flushing, headaches, and gingival hyperplasia.
Non-dihydropyridines are associated with bradycardia and can cause constipation in 25% of patients.
CCBs inhibit platelet aggregation and are associated with increased risk of gastrointestinal bleed; caution is necessary when prescribing these agents to older patients and patients with a high risk of GI bleed.
ACE Is and ARBs Side effects
The most common side effects related to ACE inhibitors are cough, hypotension, fatigue, and azotemia, Reversible renal impairment is a common side effect, especially if the patient develops volume depletion due to diarrhea or vomiting.
Cough can occur in up to 20% of patients on ACE inhibitors. It takes up to 14 to 28 days after discontinuation for the cough to resolve, the incidence of cough is less common with ARB treatment, comparing losartan with hydrochlorothiazide showed a similar incidence of cough in both medications. ARBs are safe to use in asthma patients; candesartan did not show a correlation with an increase in the incidence of cough in patients with asthma when was compared with CCBs. Ramipril demonstrated a higher rate of cough incidence comparing to telmisartan.
ACE inhibitor treatment is commonly associated with mild hyperkalemia. Even in patients with normal renal function, the risk of hyperkalemia increases in patients with renal failure, diabetes, or CHF. Ramipril and telmisartan are similar in rates of developing hyperkalemia, acute kidney injury, and syncope. but telmisartan is associated with more incidence of symptomatic hypotension.
Angioedema is a rare side effect of ACE inhibitors; it appears in 0.3 % of patients on ramipril, ARBs are less associated with angioedema comparing to ACE inhibitors.
In Black patients, ARBs correlated with less incidence of both cough and angioedema.
Beta-blockers —Common side effects of beta-blockers are bradycardia, constipation, depression, fatigue, and sexual dysfunction. Additionally, they are associated with bronchospasm and worsening symptoms of peripheral vascular disease. They can cause a flare-up of Raynaud syndrome.
Loop diuretics: are associated with electrolyte imbalance, mainly hypokalemia, hyponatremia, hypomagnesemia, and hypochloremia. Other metabolic adverse reactions are dehydration, hyperuricemia, and hyperlipidemia. Ototoxicity and deafness may occur with loop diuretics treatment.
Side effects of the Mineralocorticoid receptor antagonists: Hyperkalemia is the major side effect of this group of medications. They can cause metabolic acidosis as a result of decreased exertion of hydrogen ions. Erectile dysfunction and gynecomastia in men and irregular menstrual periods in women can occur as well.
Hydralazine: can cause headaches, flushing, palpitations, dizziness, hypotension symptoms, and dizziness as a result of the sympathetic system stimulation. It is associated with drug-induced lupus erythematosus, hemolytic anemia, and other immune phenomena.
Clonidine common side effects are drowsiness, headache, dizziness, irritability, nausea and vomiting, constipation, upper abdominal pain, and bradycardia, but other serious side effects can occur as angioedema, atrioventricular block, and severe hypotension.
Minoxidil is associated with hirsutism.
Alpha-blockers are associated with tachycardia and orthostatic hypotension as a result of venous dilation.
Thiazide type diuretics are contraindicated if the patient is anuric, and in patients with sulfonamide allergies.
CCBs are contraindicated in patients with hypersensitivity to the drug. Non-dihydropyridines contraindications are patients with heart failure with reduced ejection fraction, patients who have sick sinus syndrome, and patients with second or third-degree AV blockade. Dihydropyridine should be avoided in cardiogenic shock patients, severe aortic stenosis, and unstable angina; special caution is necessary when dihydropyridine is useful in hepatic impaired patients.
ACE inhibitors are contraindicated in patients who have a history of previous hypersensitivity to ACE inhibitors, history of ACE inhibitor-related angioedema, other types of angioedema, pregnancy, or the use of aliskiren. Relative contraindications are patients with volume depletion, abnormal renal function, and patients with aortic valve stenosis. ARBs are contraindicated in pregnancy. A combination of ACE inhibitors and ARBs is relatively contraindicated, and other relative contraindications for ARBs treatment are patients with volume depletion, patients on other medications that cause hyperkalemia, or patients with abnormal renal function.
Beta-blockers are contraindicated in asthma patients, especially the nonselective beta-blockers. Relative contraindications are hypotension and bradycardia. They should be avoided in patients with cocaine-induced coronary artery spasm.
Loop diuretics are contraindicated in patients with hypersensitivity to sulfonamides, anuric patients, and patients with hepatic coma.
Potassium-sparing diuretics are contraindicated in patients with chronic kidney disease, hyperkalemia, and caution is necessary when combining them with ACE inhibitors, ARBs, and aliskiren. They are contraindicated in patients with hypersensitivity to this class.
Clonidine is contraindicated in patients with hypersensitivity to alpha-2 agonists and should be avoided in patients with depression and recent myocardial infarctions.
Hydralazine is contraindicated if the patient has a history of hydralazine allergy, and in patients with coronary artery disease, as hydralazine can stimulate the sympathetic system, and in patients with rheumatic mitral valve disease, as pulmonary artery pressure can increase due to hydralazine treatment.
Minoxidil is contraindicated in pregnant and breastfeeding females, and patients with hypersensitivity to minoxidil.
Contraindications to alpha-blockers include patients with a history of orthostatic hypotension and patients on phosphodiesterase inhibitors.
Thiazides and loop diuretics can cause hypokalemia, while potassium-sparing diuretics cause hyperkalemia. Electrolytes should be monitored in patients on diuretics, and uric acid is recommended to be monitored in patients on thiazides and loop diuretics too. Monitoring for ototoxicity and deafness should be considered in patients on loop diuretics.
Hyperkalemia is common in ACE inhibitors and ARBs treatment, and special caution is required when they are combined with potassium-sparing diuretics. Potassium levels should be closely monitored in patients with chronic kidney disease when ACE inhibitors, ARBs, or potassium-sparing diuretics are used. ACE inhibitors and ARBs can cause acute kidney injury, and renal function requires monitoring.
Monitoring for hypotension and edema is necessary for patients on dihydropyridine CCBs. Non-dihydropyridine CCBs and beta-blockers are known to cause bradycardia, and heart rate requires monitoring, especially if these two medications are combined. QTc interval needs monitoring in patients on sotalol.
Complete blood count and ANA levels are advisable for monitoring when the patient is on hydralazine treatment. Special caution is necessary if patients develop arthralgia, fever, or other systemic symptoms.
Thiazides and loop diuretics toxicity can cause electrolyte abnormalities ( mainly hypokalemia and hyponatremia) and metabolic acidosis (hypochloremic). Severe dehydration can occur. No antidotes are available for these types of diuretics, and treatment is mainly volume and electrolytes replacement.
Potassium-sparing diuretics toxicity presents as severe hyperkalemia; the main treatment is to stop all medications that cause elevated potassium levels, IV hydration, IV calcium gluconate, IV insulin with glucose, sodium bicarbonate and potassium binding resins.
Non-dihydropyridine CCB toxicity occurs due to the decreased ionotropy effect on the cardiac muscle leading to bradycardia and hypotension. A complete heart block and idioventricular rhythm can occur. Dihydropyridine CCBs cause peripheral vasodilation and severe hypotension but have less effect on the heart rate. IV hydration is recommended for hypotension, IV atropine, and external pacemaker for bradycardia, calcium chloride or calcium gluconate intravenously can help in hypotension if IV hydration does not improve blood pressure. IV vasopressors can be an option if blood pressure does not improve.
ACE inhibitors and ARBs toxicity can cause severe hypotension, hyperkalemia, and hyponatremia. No antidotes are available, IV hydration and management for hyperkalemia are recommended.
Similar to CCBs, beta-blockers cause hypotension and bradycardia and may lead to second or third-degree AV blocks. IV glucagon is the initial antidote, IV hydration, and external pacemaker may be required if no response.
Hydralazine toxicity can cause severe hypotension, tachycardia, and skin flushing; in severe cases, patients may develop cardiac shock or myocardial ischemia. No antidote is available, IV hydration and IV vasopressors are the intervention for severe cases. Beta-blockers can be used for severe tachycardia.
Clonidine toxicity can present as lethargy, hypotension, bradycardia, and miosis. In severe cases, respiratory depression may develop. Treatment is supportive care with hydration and vasopressors, dopamine and norepinephrine are a common choice in this scenario. IV atropine is an option for severe bradycardia, and the use of an external pacemaker is reserved for cases resistant to atropine treatment.
Minoxidil toxicity can cause tachycardia and hypotension. Treatment is supportive with IV hydration and vasopressors.
Alpha-blockers toxicity can cause severe hypotension, and IV hydration and vasopressors are the primary treatment option.
Antihypertensives are a broad group of medications, and health care workers are recommended to have special caution in monitoring adherence and possible adverse reactions of these medications. Treatment of HTN is essential in preventing cardiovascular disease, and choosing the precise class of medication is essential to achieve the appropriate control with fewer side effects.
An interprofessional team of clinicians, nurses, and pharmacists is required to monitor patients on these medications. The clinician starts the antihypertensive regimen; this should be followed by special attention from the pharmacies to check on the drug-drug interactions, patient adherence to treatment, and to perform medication reconciliation. The nurse plays a vital role in monitoring the patient's adherence and determining barriers to good response to the treatment, including monitoring diet and activity levels, and evaluation of the home environment. Home visiting nurses will be able to monitor blood pressure and heart rate response to the treatment and to identify early adverse reactions. Both pharmacists and nurses should inform the clinician of any possible concerns of adherence, adverse reactions, or home environmental changes. This comprehensive interprofessional team effort helps to achieve the maximal benefits of the regimen and the best care delivery to the patient and family. [Level V]
|||Ettehad D,Emdin CA,Kiran A,Anderson SG,Callender T,Emberson J,Chalmers J,Rodgers A,Rahimi K, Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet (London, England). 2016 Mar 5 [PubMed PMID: 26724178]|
|||Armstrong C, JNC8 guidelines for the management of hypertension in adults. American family physician. 2014 Oct 1 [PubMed PMID: 25369633]|
|||Messerli FH,Bangalore S, Antihypertensive efficacy of aliskiren: is hydrochlorothiazide an appropriate benchmark? Circulation. 2009 Jan 27 [PubMed PMID: 19171867]|
|||Roush GC,Ernst ME,Kostis JB,Tandon S,Sica DA, Head-to-head comparisons of hydrochlorothiazide with indapamide and chlorthalidone: antihypertensive and metabolic effects. Hypertension (Dallas, Tex. : 1979). 2015 May [PubMed PMID: 25733245]|
|||Ernst ME,Carter BL,Goerdt CJ,Steffensmeier JJ,Phillips BB,Zimmerman MB,Bergus GR, Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure. Hypertension (Dallas, Tex. : 1979). 2006 Mar [PubMed PMID: 16432050]|
|||Olde Engberink RH,Frenkel WJ,van den Bogaard B,Brewster LM,Vogt L,van den Born BJ, Effects of thiazide-type and thiazide-like diuretics on cardiovascular events and mortality: systematic review and meta-analysis. Hypertension (Dallas, Tex. : 1979). 2015 May [PubMed PMID: 25733241]|
|||Whelton PK,Carey RM,Aronow WS,Casey DE Jr,Collins KJ,Dennison Himmelfarb C,DePalma SM,Gidding S,Jamerson KA,Jones DW,MacLaughlin EJ,Muntner P,Ovbiagele B,Smith SC Jr,Spencer CC,Stafford RS,Taler SJ,Thomas RJ,Williams KA Sr,Williamson JD,Wright JT Jr, 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension (Dallas, Tex. : 1979). 2018 Jun [PubMed PMID: 29133356]|
|||Kaplan NM, Chlorthalidone versus hydrochlorothiazide: a tale of tortoises and a hare. Hypertension (Dallas, Tex. : 1979). 2011 Dec [PubMed PMID: 22025371]|
|||Finkielman JD,Schwartz GL,Chapman AB,Boerwinkle E,Turner ST, Lack of agreement between office and ambulatory blood pressure responses to hydrochlorothiazide. American journal of hypertension. 2005 Mar [PubMed PMID: 15797660]|
|||Carey RM,Calhoun DA,Bakris GL,Brook RD,Daugherty SL,Dennison-Himmelfarb CR,Egan BM,Flack JM,Gidding SS,Judd E,Lackland DT,Laffer CL,Newton-Cheh C,Smith SM,Taler SJ,Textor SC,Turan TN,White WB, Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association. Hypertension (Dallas, Tex. : 1979). 2018 Nov [PubMed PMID: 30354828]|
|||Puttnam R,Davis BR,Pressel SL,Whelton PK,Cushman WC,Louis GT,Margolis KL,Oparil S,Williamson J,Ghosh A,Einhorn PT,Barzilay JI, Association of 3 Different Antihypertensive Medications With Hip and Pelvic Fracture Risk in Older Adults: Secondary Analysis of a Randomized Clinical Trial. JAMA internal medicine. 2017 Jan 1 [PubMed PMID: 27893045]|
|||Wright JT Jr,Probstfield JL,Cushman WC,Pressel SL,Cutler JA,Davis BR,Einhorn PT,Rahman M,Whelton PK,Ford CE,Haywood LJ,Margolis KL,Oparil S,Black HR,Alderman MH, ALLHAT findings revisited in the context of subsequent analyses, other trials, and meta-analyses. Archives of internal medicine. 2009 May 11 [PubMed PMID: 19433694]|
|||Dahlöf B,Sever PS,Poulter NR,Wedel H,Beevers DG,Caulfield M,Collins R,Kjeldsen SE,Kristinsson A,McInnes GT,Mehlsen J,Nieminen M,O'Brien E,Ostergren J, Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet (London, England). 2005 Sep 10-16 [PubMed PMID: 16154016]|
|||Weber MA,Jamerson K,Bakris GL,Weir MR,Zappe D,Zhang Y,Dahlof B,Velazquez EJ,Pitt B, Effects of body size and hypertension treatments on cardiovascular event rates: subanalysis of the ACCOMPLISH randomised controlled trial. Lancet (London, England). 2013 Feb 16 [PubMed PMID: 23219284]|
|||Yusuf S,Teo KK,Pogue J,Dyal L,Copland I,Schumacher H,Dagenais G,Sleight P,Anderson C, Telmisartan, ramipril, or both in patients at high risk for vascular events. The New England journal of medicine. 2008 Apr 10 [PubMed PMID: 18378520]|
|||Khan N,McAlister FA, Re-examining the efficacy of beta-blockers for the treatment of hypertension: a meta-analysis. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne. 2006 Jun 6 [PubMed PMID: 16754904]|
|||Thomopoulos C,Parati G,Zanchetti A, Effects of blood pressure-lowering treatment on cardiovascular outcomes and mortality: 14 - effects of different classes of antihypertensive drugs in older and younger patients: overview and meta-analysis. Journal of hypertension. 2018 Aug [PubMed PMID: 29847487]|
|||Lindholm LH,Carlberg B,Samuelsson O, Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet (London, England). 2005 Oct 29-Nov 4 [PubMed PMID: 16257341]|
|||Wald DS,Law M,Morris JK,Bestwick JP,Wald NJ, Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. The American journal of medicine. 2009 Mar [PubMed PMID: 19272490]|
|||Williams B,Mancia G,Spiering W,Agabiti Rosei E,Azizi M,Burnier M,Clement DL,Coca A,de Simone G,Dominiczak A,Kahan T,Mahfoud F,Redon J,Ruilope L,Zanchetti A,Kerins M,Kjeldsen SE,Kreutz R,Laurent S,Lip GYH,McManus R,Narkiewicz K,Ruschitzka F,Schmieder RE,Shlyakhto E,Tsioufis C,Aboyans V,Desormais I, 2018 ESC/ESH Guidelines for the management of arterial hypertension. European heart journal. 2018 Sep 1 [PubMed PMID: 30165516]|
|||James PA,Oparil S,Carter BL,Cushman WC,Dennison-Himmelfarb C,Handler J,Lackland DT,LeFevre ML,MacKenzie TD,Ogedegbe O,Smith SC Jr,Svetkey LP,Taler SJ,Townsend RR,Wright JT Jr,Narva AS,Ortiz E, 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014 Feb 5 [PubMed PMID: 24352797]|
|||Jamerson K,Weber MA,Bakris GL,Dahlöf B,Pitt B,Shi V,Hester A,Gupte J,Gatlin M,Velazquez EJ, Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. The New England journal of medicine. 2008 Dec 4 [PubMed PMID: 19052124]|
|||Bakris GL,Sarafidis PA,Weir MR,Dahlöf B,Pitt B,Jamerson K,Velazquez EJ,Staikos-Byrne L,Kelly RY,Shi V,Chiang YT,Weber MA, Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet (London, England). 2010 Apr 3 [PubMed PMID: 20170948]|
|||Phillips CO,Kashani A,Ko DK,Francis G,Krumholz HM, Adverse effects of combination angiotensin II receptor blockers plus angiotensin-converting enzyme inhibitors for left ventricular dysfunction: a quantitative review of data from randomized clinical trials. Archives of internal medicine. 2007 Oct 8 [PubMed PMID: 17923591]|
|||Huxel C,Raja A,Ollivierre-Lawrence MD, Loop Diuretics . 2020 Jan [PubMed PMID: 31536262]|
|||Sica DA,Carter B,Cushman W,Hamm L, Thiazide and loop diuretics. Journal of clinical hypertension (Greenwich, Conn.). 2011 Sep [PubMed PMID: 21896142]|
|||Bazoukis G,Thomopoulos C,Tsioufis C, Effect of mineralocorticoid antagonists on blood pressure lowering: overview and meta-analysis of randomized controlled trials in hypertension. Journal of hypertension. 2018 May [PubMed PMID: 29356711]|
|||Chapman N,Dobson J,Wilson S,Dahlöf B,Sever PS,Wedel H,Poulter NR, Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension (Dallas, Tex. : 1979). 2007 Apr [PubMed PMID: 17309946]|
|||Khosla N,Kalaitzidis R,Bakris GL, Predictors of hyperkalemia risk following hypertension control with aldosterone blockade. American journal of nephrology. 2009 [PubMed PMID: 19738369]|
|||[PubMed PMID: 26414968]|
|||[PubMed PMID: 30422513]|
|||[PubMed PMID: 31543812]|
|||[PubMed PMID: 29494080]|
|||Herman LL,Padala SA,Bashir K, Angiotensin Converting Enzyme Inhibitors (ACEI) . 2020 Jan [PubMed PMID: 28613705]|
|||Farzam K,Jan A, Beta Blockers . 2020 Jan [PubMed PMID: 30422501]|
|||Herman LL,Tivakaran VS, Hydralazine . 2020 Jan [PubMed PMID: 29262006]|
|||Alpha 1 Adrenergic Receptor Antagonists . 2012 [PubMed PMID: 31644028]|
|||Bulsara KG,Cassagnol M, Amlodipine . 2020 Jan [PubMed PMID: 30137793]|
|||Khan KM,Patel J,Schaefer TJ, Nifedipine . 2020 Jan [PubMed PMID: 30725737]|
|||Talreja O,Cassagnol M, Diltiazem . 2020 Jan [PubMed PMID: 30422532]|
|||Fahie S,Cassagnol M, Verapamil . 2020 Jan [PubMed PMID: 30860730]|
|||Hill RD,Vaidya PN, Angiotensin II Receptor Blockers (ARB, ARb) . 2020 Jan [PubMed PMID: 30725712]|
|||Yasaei R,Saadabadi A, Clonidine . 2020 Jan [PubMed PMID: 29083638]|
|||Taylor BN,Cassagnol M, Alpha Adrenergic Receptors . 2020 Jan [PubMed PMID: 30969652]|
|||Leung AA,Wright A,Pazo V,Karson A,Bates DW, Risk of thiazide-induced hyponatremia in patients with hypertension. The American journal of medicine. 2011 Nov [PubMed PMID: 22017784]|
|||[PubMed PMID: 21295192]|
|||Desai AS,Swedberg K,McMurray JJ,Granger CB,Yusuf S,Young JB,Dunlap ME,Solomon SD,Hainer JW,Olofsson B,Michelson EL,Pfeffer MA, Incidence and predictors of hyperkalemia in patients with heart failure: an analysis of the CHARM Program. Journal of the American College of Cardiology. 2007 Nov 13 [PubMed PMID: 17996561]|
|||Badri T,Kumar D D, Minoxidil . 2020 Jan [PubMed PMID: 29494000]|
|||Goyal A,Cusick AS,Thielemier B, ACE Inhibitors . 2020 Jan [PubMed PMID: 28613646]|
|||[PubMed PMID: 31194443]|
|||Kandler MR,Mah GT,Tejani AM,Stabler SN,Salzwedel DM, Hydralazine for essential hypertension. The Cochrane database of systematic reviews. 2011 Nov 9 [PubMed PMID: 22071816]|
|||Iyer P,Dirweesh A,Zijoo R, Hydralazine Induced Lupus Syndrome Presenting with Recurrent Pericardial Effusion and a Negative Antinuclear Antibody. Case reports in rheumatology. 2017 [PubMed PMID: 28194293]|
|||Manzon L,Nappe TM,Maguire NJ, Clonidine Toxicity . 2020 Jan [PubMed PMID: 29083752]|
|||Yang CH,Raja A, Terazosin . 2020 Jan [PubMed PMID: 31424792]|